Core Viewpoint - Yangli Pharmaceutical has completed a significant B round financing, which will be used to advance multiple products in clinical trials, focusing on innovative drugs for oncology and chronic diseases [2][6]. Group 1: Company Overview - Yangli Pharmaceutical, founded in 2021 and based in Hangzhou, focuses on developing innovative Class 1 drugs with global intellectual property rights, targeting unmet clinical needs in oncology and chronic disease therapies [2][6]. - The company has a strong founding team with members from prestigious institutions such as Tsinghua University and UCLA, bringing extensive experience in drug development and management [3][5]. Group 2: Product Development - The company has several products in clinical phases, including high-selectivity aldosterone synthase inhibitor VB19055 and small molecule targeted drugs TFX05, TFX06, and VB15, covering various diseases such as hypertension and multiple solid tumors [5]. - Yangli Pharmaceutical's pipeline includes preclinical small molecules and small nucleic acid therapies targeting tumors, hypertension, hyperlipidemia, and diabetes [5]. Group 3: Financing and Future Plans - The recent financing round, led by Qiming Venture Partners, reflects investor confidence in the clinical competitiveness and market potential of Yangli Pharmaceutical's pipeline [2][6]. - The completion of this financing is expected to facilitate the entry of the oncology product line into registration clinical trials and provide clinical validation for chronic disease products, marking a significant step towards commercialization [6].